• EU green light for Chiesi’s Lamzede pharmatimes
    July 18, 2018
    European regulators have green-lighted Chiesi’s Lamzede as the first long-term enzyme replacement therapy to treat non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.
  • NICE rejects Chiesi’s Lamzede pharmatimes
    July 11, 2018
    It is currently looking unlikely that Chiesi’s Lamzede will become routinely available on the NHS for patients with alpha-mannosidosis, after cost-regulators issued a preliminary rejection of the drug.
PharmaSources Customer Service